Hep­tares bags GPCR tech in $12M G7 buy­out; Pfiz­er re­ports PhI­II suc­cess for Her­ceptin biosim

Lon­don-based Hep­tares has struck a deal to buy Switzer­land’s G7 Ther­a­peu­tics for about $12 mil­lion. Hep­tares was lured to the deal by G7’s ex­per­tise in G pro­tein-cou­pled re­cep­tors (GPCRs). G7 isn’t dis­ap­pear­ing. It will be­come the new Zurich-based sub­sidiary for Hep­tares, which likes the tech add that ex­pands its work with their STaR plat­form.

Rack up an­oth­er Phase III suc­cess in the grow­ing biosim­i­lar sec­tor. Pfiz­er, which is now big in­to bi­o­log­ic knock­offs, says its copy­cat of Her­ceptin came through in a late-stage study. The pri­ma­ry end­point looked at the ob­jec­tive re­sponse rate in a head-to-head com­par­i­son on HER2-pos­i­tive breast can­cer, where Her­ceptin orig­i­nal­ly made a huge splash in the can­cer mar­ket. Old drugs like Her­ceptin, Hu­mi­ra and Avastin have been the tar­get of a long line­up of biosim­i­lar man­u­fac­tur­ers, who will soon start carv­ing in to some of the world’s biggest drug fran­chis­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER